Here we showed that the chromosome 17q23 amplification in the HER2+ breast cancer results in aberrant elevation of WIP1 and miR-21, which not only contributes to breast tumorigenesis, but also causes resistance to anti-HER2 therapy. This evidence concerns the gene PPM1D and breast cancer.